Scailyte CHU Rennes announce Covid-19 partnership. Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 3.1 million in a pre-Series A round led by Swisscom Ventures.
Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is
supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning
several national and international start-up competitions, and is the beneficiary of significant research
grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial
Intelligence, Software development, Finance, Marketing and Sales.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised
pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and
have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
Recent News
World CB & CDx Summit 2024
Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
World CB & CDx Summit 2024
Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...